Life Science Investing Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
Life Science Investing Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
Life Science Investing Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
